Stay up-to-date with the latest FDA approvals, trial readouts, and key clinician insights across cardiovascular care.
News|Articles|April 6, 2026
ACC.26 Recap: 6 Practice-Changing Trials to Know
Author(s)Ryan Livingston
Fact checked by: Patrick Campbell
Catch up on data from some of the most impactful trials presented at the American College of Cardiology 2026.
Advertisement
Advertisement
The
Related to this article
Catch up on key FDA approvals, major trial updates, and critical clinician insights from the last 3 months.
Jesus Almendral, MD, and Kanika Mody, MD, join the HCPLive team to discuss increases in hypertensive heart disease, heart failure, and other conditions.
Get a head start on one of the biggest heart failure conferences of the year with our HFSA 2026 preview.
FDA approved mavacamten for oHCM in children weighing 30 kg or more after SCOUT-HCM showed a 48.0-mm Hg Valsalva LVOT gradient reduction vs placebo.
In a phase 3 study, telikibart achieved EASI-75 in 69.6% of adult patients with atopic dermatitis at Week 16, with rates above 94% by Week 52.
An indirect comparison finds higher placebo-adjusted skin and itch responses with upadacitinib vs nemolizumab in atopic dermatitis.
Check out highlights from news published on Day 3 of the EADV Congress 2026, spanning psoriasis, cutaneous lupus, atopic dermatitis, and more.
Advertisement
Advertisement